What the FDA labels say about taking them together
Tranylcypromine and vilazodone
Tranylcypromine's FDA label of July 2, 2025 names vilazodone in its boxed warning section; vilazodone's label does not name tranylcypromine itself but warns about its class (MAO inhibitors). The tranylcypromine label: “… antidepressants Amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine; Clinical Comment on Concomitant Use a: Contraindicated a; …”
Check it at the source: the tranylcypromine FDA label on DailyMed (effective July 2, 2025, Advanz Pharma (US) Corp.); the vilazodone FDA label on DailyMed (effective May 22, 2024, Teva Pharmaceuticals, Inc.).
What does the tranylcypromine label say about vilazodone?
Tranylcypromine label, boxed warningSee, "What is the most important information I should know about PARNATE?” and “What are the possible side effects of PARNATE?” Do not take PARNATE if you: take certain medicines, including: antidepressants, such as: other monoamine oxidase inhibitors (MAOIs) selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) tricyclic antidepressants other antidepressants, such as amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine amphetamines and methylphenidates medicines that can raise blood pressure (sympathomimetic medicine), such as pseudoephedrine, phenylephrine and ephedrine.
Tranylcypromine label, contraindicationsOther monoamine oxidase inhibitors (MAOIs) Selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) Tricyclic antidepressants Other antidepressants (e.g., amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine) Amphetamines and methylphenidates and derivatives Sympathomimetic products (e.g., cold, hay fever or weight reducing products that contain vasoconstrictors such as pseudoephedrine, phenylephrine, and ephedrine; …
Tranylcypromine label, drug interactionsProduct: Antidepressants including but not limited to: Other MAOIs (e.g., linezolid, intravenous methylene blue, selective MAOIs) Selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) Tricyclic antidepressants Amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine; Clinical Comment on Concomitant Use a: Contraindicated a; Predominant Effect/Risk [Hypertensive Reaction (HR) b or Serotonin Syndrome (SS) c ]: SS for all antidepressants For MAOIs, increased MAO inhibition and risk of adverse reactions, SS, and HR g
Source: FDA drug label (PARNATE), Advanz Pharma (US) Corp., effective July 2, 2025 (SPL set b72d8187-dfcc-4ea0-b5e9-c0be95b69a27), via openFDA; the full label on DailyMed
What does the vilazodone label say about tranylcypromine?
Vilazodone's label does not name tranylcypromine itself; it warns about its class (MAO inhibitors):
Vilazodone label, contraindicationsPatients taking, or within 14 days of stopping, monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Warnings and Precautions ( 5.2 ), Drug Interactions ( 7 )].
Vilazodone label, contraindicationsPatients taking, or within 14 days of stopping, monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Warnings and Precautions ( 5.2 ), Drug Interactions ( 7 )]. Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs.
Source: FDA drug label (Vilazodone Hydrochloride), Teva Pharmaceuticals, Inc., effective May 22, 2024 (SPL set 3a4745a0-de23-4b40-923e-0d7dfe6b8634), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Tranylcypromine | Vilazodone | |
|---|---|---|
| Labeled for | Depression | Depression |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.591 per tablet 10 mg tablet | $0.732 per tablet 10 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once